[
 {
  "title": "Screening and Treatment for Prostate Cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted Schaeffer presents the roadmap for the best way to screen for, and treat, prostate cancer. We also get into the “mass screening” controversy and all the risks involved with treatment.",
  "content_length": 187,
  "content_tokens": 41,
  "embedding": []
 },
 {
  "title": "Exciting Areas of Cancer Research",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "In addition, we discuss our evolving understanding of cancer and the most exciting areas of research to come.",
  "content_length": 109,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "History of prostate surgery and Pat Walsh’s legendary work in prostate cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "History of prostate surgery, and Pat Walsh’s legendary work in prostate cancer [36:15];",
  "content_length": 87,
  "content_tokens": 21,
  "embedding": []
 },
 {
  "title": "Prostate surgery and the risks involved with treatment",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Prostate surgery and the risks involved with treatment [53:00];",
  "content_length": 63,
  "content_tokens": 14,
  "embedding": []
 },
 {
  "title": "Screening for prostate cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Screening for prostate cancer [58:00];",
  "content_length": 38,
  "content_tokens": 10,
  "embedding": []
 },
 {
  "title": "The “mass screening” controversy",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The “mass screening” controversy [1:12:45];",
  "content_length": 43,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Biopsies and MRI: important things to know",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Biopsies and MRI: important things to know [1:25:30];",
  "content_length": 53,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "Testosterone, DHT and the prostate cancer controversy",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Testosterone, DHT and the prostate cancer controversy [1:53:15];",
  "content_length": 64,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "The metabolism of the prostate",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The metabolism of the prostate [2:03:00];",
  "content_length": 41,
  "content_tokens": 12,
  "embedding": []
 },
 {
  "title": "The most exciting areas of research in prostate cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The most exciting areas of research in prostate cancer [2:08:00];",
  "content_length": 65,
  "content_tokens": 16,
  "embedding": []
 },
 {
  "title": "Benign issues involving the prostate: pelvic pain, infections and treatments",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Benign issues involving the prostate: pelvic pain, infections and treatments [2:11:15];",
  "content_length": 87,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Prostate Cancer Screening and Treatment",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted Schaeffer, Professor and Chair of the Department of Urology at Northwestern, presents the roadmap for the best way to screen for, and treat, prostate cancer. We also get into the “mass screening” controversy and all the risks involved with treatment.",
  "content_length": 254,
  "content_tokens": 54,
  "embedding": []
 },
 {
  "title": "Evolution of Cancer Research",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "In addition, we discuss our evolving understanding of cancer and the most exciting areas of research to come.",
  "content_length": 109,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Screening for Prostate Cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted presents the roadmap for the best way to screen for, and treat, prostate cancer. Screening for prostate cancer is discussed at 58:00.",
  "content_length": 137,
  "content_tokens": 30,
  "embedding": []
 },
 {
  "title": "The Risks Involved with Prostate Cancer Treatment",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted discusses the risks involved with prostate cancer treatment at 53:00.",
  "content_length": 73,
  "content_tokens": 14,
  "embedding": []
 },
 {
  "title": "The Mass Screening Controversy",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The mass screening controversy is discussed at 1:12:45.",
  "content_length": 55,
  "content_tokens": 13,
  "embedding": []
 },
 {
  "title": "Exciting Areas of Research in Prostate Cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The most exciting areas of research in prostate cancer are discussed at 2:08:00.",
  "content_length": 80,
  "content_tokens": 18,
  "embedding": []
 },
 {
  "title": "Benign Issues Involving the Prostate",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Benign issues involving the prostate, such as pelvic pain, infections, and treatments, are discussed at 2:11:15.",
  "content_length": 112,
  "content_tokens": 26,
  "embedding": []
 },
 {
  "title": "Tyrosine kinase: what it is and why it’s relevant",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted’s PhD work focused on tyrosine kinase: “So it turns out that the tyrosine kinases that I worked on my PhD are really involved in fine tuning the T-cell receptor signaling . . . they really fine tuned the signal. It’s not off or on.”\n\nWe all have unique DNA in every cell in our body\nBut within each person, there is variability with what the cells do with the DNA code\nAnd exposure to environment, for example, can result in epigenetic change\nThis change results in a protein\n\nProteins\n\nThey are not inert, they can change\nPieces of the proteins can be modified through kinases\nTyrosine kinase is just one type of kinase\nKinases have become a very attractive target for drugs\n\nDrugs target kinases\n⇒ The idea in cancer biology is to find alterations to find mutations to find changes that you can “target” to do precision oncology, precision medicine. And so these are one of the ways that we’re beginning to think about advancing the medicine in that special way.\n\nGleevec\n\nGleevec, for example, targets a specifically altered/fused gene of tyrosine kinase\nIt is able to cure chronic myeloid cancer (CML) ⇒ this is an exception, however, in that it targets a single gene and has a curative effect\n\n“But for most cancer a single agent like Gleevec isn’t going to work because the [cancer] cells change and alter, but doing double or triple targeting will be an effective long term approach for those. Just like we’ve learned from HIV management.”",
  "content_length": 1450,
  "content_tokens": 365,
  "embedding": []
 },
 {
  "title": "Translation and Clinical Experience",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Have a clear understanding of this idea of translation: You can do science for science sake, but to me to make really big impacts, you have to be able to translate that to the human condition. Get some clinical time in BEFORE doing your PhD ⇒ you will know really key nuances that were important for understanding the right questions to ask.",
  "content_length": 341,
  "content_tokens": 68,
  "embedding": []
 },
 {
  "title": "Why Urology and Hopkins?",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Father was a urologist. Ted’s grandfather got sick and died of prostate cancer. Also wanted to work with his hands. Decided he wanted to be a prostate cancer scientist and surgeon. Best urology program in the US. Chairman was Pat Walsh, the godfather of urology and prostate cancer surgery. The people at Hopkins are amazing.",
  "content_length": 325,
  "content_tokens": 72,
  "embedding": []
 },
 {
  "title": "Pat Walsh's Approach to Prostate Surgery",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "For blood loss… He understood where the veins were and he controlled them by suturing them before they started bleeding. By doing that, you could actually see everything. (like going from operating in the dark to in the daylight). For retaining potency: this was not so obvious, but he figured that part out by working with some anatomists and really just studying and talking to his patients and listening to what they had to say. He would record and rewatch all his cases to learn from his mistakes.",
  "content_length": 501,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Prostate Surgery and Risks",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Odds of regaining sexual function and having no problems with urinary leakage? Not 100%, and it’s because the nerves are not myelinated. Nearly all other nerves in the body have myelination. Urinary leakage: About 4% of cases, on average, have urinary leakage (more common in women and older men). Only 2% of Ted’s patients report urinary leakage. Sexual function: For a 50 year old man, over 90% will regain function (if Ted’s patient). But ED is an age-related dysfunction, so the older the patient the higher the chance of not fully regaining function.",
  "content_length": 555,
  "content_tokens": 131,
  "embedding": []
 },
 {
  "title": "The Neurovascular Bundle of Walsh",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The neurovascular bundle of Walsh",
  "content_length": 33,
  "content_tokens": 7,
  "embedding": []
 },
 {
  "title": "Prostate-specific antigen (PSA)",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "PSA is a protein made by the prostate. It’s function is to liquefy semen. Some PSA gets into the bloodstream (some is normal for everyone). The bigger the prostate, the more PSA leaks into the blood. The older the person, generally the more PSA in blood. An infection or cancer in the prostate can make the PSA rise besides just getting older and having a larger prostate. A 40 year old is around .5 to .6 nanograms per ml. A 50 year old, the normal is 1.0. No PSA number, no matter how low, guarantees that you don’t have cancer. But for a younger person, higher than 2.5 is cause for more workup. An older person, higher than 4.0 is concerning. But not yet time for a biopsy.",
  "content_length": 677,
  "content_tokens": 173,
  "embedding": []
 },
 {
  "title": "Percent free PSA",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Percent free PSA was the first way that urologists began to look at what’s the chance that a PSA of 4.0 is coming from a cancer versus a PSA of 4.0 coming from just benign overgrowth. A high percent free PSA is associated with a big prostate and less of a chance of prostate cancer. A low percent free PSA is associated with a higher likelihood that that PSA’s produced from a gland with prostate cancer in it.",
  "content_length": 410,
  "content_tokens": 100,
  "embedding": []
 },
 {
  "title": "PSA density",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "PSA density is the PSA number divided by volume of prostate. PSA density more than .1 or .15 raises a red flag. So an 80 gram prostate (which is big) with a PSA of 4.0 is a density of .05, on avg. that person does not have cancer.",
  "content_length": 230,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "Four-kallikrein test (4k score) and the Prostate Health Index (PHI)",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Two new tests that leverage off the idea that prostate cancer cells make PSA differently than benign prostate cells. Both tests are equally accurate and interchangeable. 4k test has figured out a way to give a binary answer. Below 7.5% means you have a 1.6 percent chance to die in 20 years. Above 7.5% means you have a continuous variable chance the higher the percentage.",
  "content_length": 373,
  "content_tokens": 80,
  "embedding": []
 },
 {
  "title": "Prostate Cancer Epidemic",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "In the 1940s, 40% of men coming in with prostate cancer had metastatic at presentation. Epidemic of deaths of prostate cancer.",
  "content_length": 126,
  "content_tokens": 29,
  "embedding": []
 },
 {
  "title": "Controversy over Mass Screening",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The idea of “mass screening” controversy began. The argument against mass screening is that it would lead to people being treated who didn’t need it, and the treatment process is not safe or cheap and can be hard on people. Skeptics said it was a way for urologists to make money.",
  "content_length": 280,
  "content_tokens": 66,
  "embedding": []
 },
 {
  "title": "Not All Prostate Cancer is Lethal",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Not all prostate cancer is lethal. Initially we developed a biomarker to pick up all prostate cancers ⇒ the PSA blood test. We picked them up, we treated them, we reduced deaths but we also over-treated people. People who had a cancer that would never have been lethal in their lifetime, so the screening tools got better (4k, PHI, etc.).",
  "content_length": 338,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Screening Protocol Today",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The over-simplified screening protocol of today. PSA test first (including free PSA, PSA density). However, it’s important to not in 10-15% of men with a “normal” PSA can still have a lethal type of cancer. If abnormal, then move to 4k/PHI. If that’s abnormal, get an MRI. If abnormal, get a biopsy.",
  "content_length": 299,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Biopsies and MRI",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Biopsies and MRI: important things to know. What is a prostate biopsy? ⇒ a procedure to remove samples of suspicious tissue from the prostate to test for cancer. Relatively safe now. Risks involved with biopsies. Bleeding after the procedure. Usually just a small amount in a bowel movement. 1 or 2% will visit hospital with trouble urinating due to a swollen prostate. Only a small percentage will get an infection and need to visit the hospital (only 0.4% of Ted’s patients). What to do before deciding on a biopsy? Get a PHI or 4K score (FYI, these tests perform equally well across demographics). If abnormal, get an MRI. You want a multiparametric prostate MRI. The most important parameter in the multiparametric MRI is actually the diffusion weighted imaging.",
  "content_length": 766,
  "content_tokens": 171,
  "embedding": []
 },
 {
  "title": "Multinational prospective clinical trial for prostate cancer screening",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "A multinational prospective clinical trial was conducted to study the utility of MRI for screening for prostate cancer. If there is an abnormality on the MRI, a biopsy is recommended. The suspicious lesion plus a sextant biopsy should be done. If the PHI and 4k tests are abnormal, a multiparametric prostate MRI is recommended. If the MRI looks abnormal, a sextant biopsy is recommended. If the PSA density is high, a biopsy is recommended. If they have an MRI, no lesion, and a low PSA density, they don’t need a biopsy.",
  "content_length": 522,
  "content_tokens": 125,
  "embedding": []
 },
 {
  "title": "Urology and prostate cancer screening",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Urology is a great field of medicine, and patients are appreciative. Ted says that in urology, you “own the diagnosis” unlike other fields. Peter wants goats, and Ted recommends getting a pygmy goat. Ted worked with Ben Stiller, who is now an advocate for the importance of screening and treating prostate cancer.",
  "content_length": 313,
  "content_tokens": 70,
  "embedding": []
 },
 {
  "title": "Gleason grading system",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The Gleason grading system is a way to measure the aggressiveness of a cancer when looking at samples from a biopsy. The Gleason sum is calculated by adding the score of the most prevalent abnormality on the view of the tumor and the score of the second most common glandular architecture. The Gleason grade group goes between 1 and 5, and it translates very nicely into clinical outcomes. Before knowing the Gleason grade, all other factors such as 4k score, PSA numbers, MRI, etc. are still relevant.",
  "content_length": 502,
  "content_tokens": 107,
  "embedding": []
 },
 {
  "title": "Genetic testing for prostate cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted does not generally use genetic testing for prostate cancer. PSA density performs just as well as genetic testing in most cases. Testing is not done if the results will not matter or change what is recommended.",
  "content_length": 213,
  "content_tokens": 41,
  "embedding": []
 },
 {
  "title": "Testosterone, DHT and the prostate cancer controversy",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Relationship between 5-alpha-reductase inhibitors and prostate cancer. The Prostate Cancer Prevention Trial showed that lowering DHT could reduce the risk of prostate cancer. But one of the problems was that there was increased detection of more aggressive cancers in men taking the drug to lower DHT. Peter and Ted believe that it is selecting for it because any cancer that comes out of low DHT environment must be strong. Ted collaborated with Elai Davicioni and his company, GenomeDx, to look at the biology of prostate cancers, how aggressive they were, and compare the aggressiveness of the prostate cancer with the androgen output of the tumor. Ted has shown that these low androgen output tumors are the most aggressive tumors. Very high androgen tumors are also aggressive, but they’re exquisitely sensitive to androgen deprivation, which is one of the mainstays of treatment for metastatic prostate cancer.",
  "content_length": 916,
  "content_tokens": 188,
  "embedding": []
 },
 {
  "title": "Does testosterone replacement therapy cause prostate cancer?",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Ted says, “I don’t see any clear evidence that physiologic replacement of testosterone is going to accelerate or cause a cancer to develop.”",
  "content_length": 140,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "The metabolism of the prostate",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "David Guis is making progress in this space. He has a lot of really interesting data looking at the sirtuin pathways through mitochondria regulating the hormonal dependency or hormonal regulation of prostate cancer. He has a SIRT3 manganese superoxide dismutase pathway worked out and it regulates resistance to Tamoxifen and luminal B breast cancer. So it could be up-regulating or down-regulating androgen production basically. Ted thinks that there’s something about metabolism in the prostate. He thinks it’s hard to study. The most exciting areas of research in prostate cancer.",
  "content_length": 583,
  "content_tokens": 124,
  "embedding": []
 },
 {
  "title": "Predictive Biomarkers in Urologic Oncology",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "The most exciting stuff in urologic oncology is really moving beyond these prognostic biomarkers to predictive biomarkers you can pick up in the DNA of a tumor or the DNA of a patient. Particularly BRCA1, BRCA2, ATM loss . . . “these different kinds of DNA damage repair pathways that people didn’t really think matter for prostate, we now know within the last three years that they really matter.”",
  "content_length": 398,
  "content_tokens": 94,
  "embedding": []
 },
 {
  "title": "Mutations in Metastatic Castrate-Resistant Prostate Cancer",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Pete Nelson paper showing that about 11 to 12% of men with metastatic castrate-resistant prostate cancer had mutations, particularly BRCA2, BRCA1, ATM, RAD51: Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects (Frank et al., 2018). If you look in the tumors of men with metastatic castrate-resistant prostate cancer, depending on where you look, over one third of the tumors, the cells will have mutations in these pathways, which makes them incredibly sensitive to PARP inhibition, so that’s a huge game changer.",
  "content_length": 589,
  "content_tokens": 129,
  "embedding": []
 },
 {
  "title": "Genomic Alterations and Immunotherapy",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Also, the total genomic score, or the alterations in the genome of the individual cancer cells, and will that make them more sensitive to immunotherapy or not? That’s more coming online, but the idea that there are things in the somatic DNA of the tumor cells and in the germline of individuals that you can use to screen for not only prostate, but breast, pancreas, etc, that’s a huge game changer.",
  "content_length": 399,
  "content_tokens": 93,
  "embedding": []
 },
 {
  "title": "Prostatitis",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Peter had severe burning while peeing. Not a UTI. Called Ted, agreed it could be prostatitis. Ted’s dad’s paper. Prostatitis can be caused by an infection, or just inflammation. Ted suspected inflammation. Before taking antibiotics, Ted said go and get a prostate massage so we can check the fluids for infection. Peter said 3 days after massage, he felt great, never took antibiotics. Peter said the massage was extremely painful, here’s how he felt: So what Peter had was nonbacterial prostatitis (inflammation in the prostate). This falls into the bucket of “chronic pelvic pain”. Not so sure what causes it other than constipation.",
  "content_length": 635,
  "content_tokens": 148,
  "embedding": []
 },
 {
  "title": "Robot Surgery and Male Contraceptives",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "All of Ted’s surgeries are now with the help of a robot. Some stuff that can block testosterone in the testicle, some coming soon. Safe procedure for sure (maybe freeze some sperm first). Over 90% are reversible with a good procedure.",
  "content_length": 234,
  "content_tokens": 52,
  "embedding": []
 },
 {
  "title": "Peter's Choice of Daily Vehicle",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Peter's choice of daily vehicle is the Porsche 911 Turbo.",
  "content_length": 57,
  "content_tokens": 12,
  "embedding": []
 },
 {
  "title": "Other Cars Mentioned",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Other cars mentioned by Peter include the Ferrari 458, Ferrari 488, McLaren P1, McLaren Senna, McLaren 720S, LaFerrari, and Porsche 918 Spyder.",
  "content_length": 143,
  "content_tokens": 38,
  "embedding": []
 },
 {
  "title": "Driver Peter Follows on YouTube",
  "date": "February 4, 2019",
  "context": "Cancer",
  "people": "Peter Attia",
  "content": "Peter follows Chris Harris on Cars, a car reviewer on YouTube.",
  "content_length": 62,
  "content_tokens": 13,
  "embedding": []
 }
]